OQL 071
Alternative Names: OQL-071Latest Information Update: 28 May 2026
At a glance
- Originator OnQuality Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia
Most Recent Events
- 28 May 2026 No recent reports of development identified for research development in Alopecia in USA
- 07 Apr 2022 Early research in Alopecia in USA (unspecified route) prior to April 2022 (OnQuality Pharmaceutical's pipeline, April 2022)